Defining treatment failure in severe osteoporosis.

[1]  N. Watts,et al.  Vertebral Fracture Risk Is Reduced in Women Who Lose Femoral Neck BMD With Teriparatide Treatment , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  C. Roux,et al.  Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis , 2009, Osteoporosis International.

[3]  C. Roux,et al.  Radiographic methods for evaluating osteoporotic vertebral fractures. , 2009, Joint, bone, spine : revue du rhumatisme.

[4]  C. Roux,et al.  Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience , 2009, Osteoporosis International.

[5]  G. de Pouvourville,et al.  A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  G. de Pouvourville,et al.  Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. , 2008, Clinical therapeutics.

[7]  J. Reginster,et al.  Vitamin D inadequacy in French osteoporotic and osteopenic women. , 2008, Joint, bone, spine : revue du rhumatisme.

[8]  A. Díez-Pérez,et al.  Inadequate responders to osteoporosis treatment: proposal for an operational definition , 2008, Osteoporosis International.

[9]  T. Spector,et al.  Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. , 2008, Arthritis and rheumatism.

[10]  C. Cooper,et al.  Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO) , 2008, Osteoporosis International.

[11]  C. Roux,et al.  A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. , 2008, Joint, bone, spine : revue du rhumatisme.

[12]  E. Seeman.  Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? , 2007, Bone.

[13]  Jean-Pierre Devogelaer,et al.  Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. , 2007, The Journal of clinical endocrinology and metabolism.

[14]  J. Reginster,et al.  Adherence to treatment of osteoporosis: a need for study , 2007, Osteoporosis International.

[15]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[16]  J. Cramer,et al.  A systematic review of persistence and compliance with bisphosphonates for osteoporosis , 2007, Osteoporosis International.

[17]  S. Adami,et al.  Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  S. Silverman,et al.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.

[19]  C. Cooper,et al.  Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). , 2006, QJM : monthly journal of the Association of Physicians.

[20]  E. Brankin,et al.  Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study , 2006, International journal of clinical practice.

[21]  F. Duboeuf,et al.  Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture , 2006, Osteoporosis International.

[22]  C. Christiansen,et al.  Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. , 2006, Arthritis and rheumatism.

[23]  P. Delmas,et al.  Drug Insight: bisphosphonates for postmenopausal osteoporosis , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[24]  S. Giannini,et al.  Determinants of adherence to osteoporosis treatment in clinical practice , 2006, Osteoporosis International.

[25]  J. Avorn,et al.  Compliance with osteoporosis medications. , 2005, Archives of internal medicine.

[26]  S. Cummings,et al.  Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial , 2005, Osteoporosis International.

[27]  H. Genant,et al.  Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[30]  Johanna W Lampe,et al.  Antibiotic use in relation to the risk of breast cancer , 2004, JAMA.

[31]  S. Boonen,et al.  Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.

[32]  Jacques P. Brown,et al.  What predicts early fracture or bone loss on bisphosphonate therapy? , 2003, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[33]  E. Lewiecki.  Nonresponders to osteoporosis therapy. , 2003, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[34]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[35]  G. Ferrara,et al.  Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. , 2000, The Journal of rheumatology.

[36]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[37]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[38]  Christian Roux,et al.  Vertebral Fracture Assessment: the 2007 ISCD Official Positions. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[39]  R. Porcher,et al.  Diagnosis of vertebral fractures by vertebral fracture assessment. , 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[40]  L. Ferrar,et al.  Vertebral fracture assessment: the 2005 ISCD Official Positions. , 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.